Volume 27, Number 9—September 2021
Research
Development and Clinical Evaluation of a CRISPR-Based Diagnostic for Rapid Group B Streptococcus Screening
Table
Assay and result | CRISPR-GBS |
% (95% CI) |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Sensitivity |
Specificity |
Positive predictive value |
Negative predictive value |
|||||||||
Positive | Negative | Total | ||||||||||
Direct culture | ||||||||||||
Positive | 52 | 3 | 55 | 94.5 (83.9–98.6) |
89.6 (85.9–92.5) |
58.4 (47.5–68.6) |
99.1 (97.1–99.8) |
|||||
Negative | 37 | 320 | 357 | |||||||||
Total |
89 |
323 |
412 |
|||||||||
PCR | ||||||||||||
Positive | 54 | 3 | 57 | 94.7 (84.5–98.6) |
90.1 (86.4–92.9) |
60.7 (49.7–70.7) |
99.1 (97.1–99.8) |
|||||
Negative | 35 | 320 | 355 | |||||||||
Total |
89 |
323 |
412 |
|||||||||
Direct culture and PCR | ||||||||||||
Positive | 47 | 3 | 50 | 94.0 (82.5–98.4) |
91.4 (87.9–94.0) |
61.0 (49.2–71.7) |
99.0 (97.1–99.8) |
|||||
Negative | 30 | 320 | 350 | |||||||||
Total |
77 |
323 |
400 |
|||||||||
Enriched culture | ||||||||||||
Positive | 22 | 0 | 22 | 100 (81.5–100.0) | 100 (62.9–100.0) | 100 (81.5–100.0) | 100 (62.9–100.0) | |||||
Negative | 0 | 9 | 9 | |||||||||
Total | 22 | 9 | 31 |
1These authors contributed equally to this article.
Page created: July 14, 2021
Page updated: August 25, 2021
Page reviewed: August 25, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.